posted on
Apr 05, 2022 08:47PM

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Message: Re: Debt
Hey Narmac, although I largely agree with most of your opinions regarding Zenith's CEO, I do think when it comes to a potential sale of the company that the involvement of Eastern will have a big influence on the pricing of any sale. I believe Eastern is still the largest shareholder in Zenith and are very much aligned with the small shareholders in the company. They don't appear to have any special interest in Zenith other than as an asset which will hopefully someday (soon!!!!?) produce a good ROI.
As we've discussed previously, Zenith would now appear to be more advanced than Constellation so hopefully that bodes well for what Zenith is actually worth in a sale as opposed to the very low value McCaffrey seems to be ascribing to the company with his decreasing price point in private placements. My opinion is that the low private placement pricing is more indicative of a CEO who is just lousy at his job as opposed to being reflective of the science in the company.
7 Recommendations
Loading...
Loading...
New Message
Please
login
to post a reply